BACKGROUND: Sarcoplasmic reticulum (SR) Ca(2+) leak through ryanodine receptor type 2 (RyR2) dysfunction is of major pathophysiological relevance in human heart failure (HF); however, mechanisms underlying progressive RyR2 dysregulation from cardiac hypertrophy to HF are still controversial. METHODS AND RESULTS: We investigated healthy control myocardium (n=5) and myocardium from patients with compensated hypertrophy (n=25) and HF (n=32). In hypertrophy, Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) and protein kinase A (PKA) both phosphorylated RyR2 at levels that were not different from healthy myocardium. Accordingly, inhibitors of these kinases reduced the SR Ca(2+) leak. In HF, however, the SR Ca(2+) leak was nearly doubled compared with hypertrophy, which led to reduced systolic Ca(2+) transients, a depletion of SR Ca(2+) storage and elevated diastolic Ca(2+) levels. This was accompanied by a significantly increased CaMKII-dependent phosphorylation of RyR2. In contrast, PKA-dependent RyR2 phosphorylation was not increased in HF and was independent of previous β-blocker treatment. In HF, CaMKII inhibition but not inhibition of PKA yielded a reduction of the SR Ca(2+) leak. Moreover, PKA inhibition further reduced SR Ca(2+) load and systolic Ca(2+) transients. CONCLUSIONS: In human hypertrophy, both CaMKII and PKA functionally regulate RyR2 and may induce SR Ca(2+) leak. In the transition from hypertrophy to HF, the diastolic Ca(2+) leak increases and disturbed Ca(2+) cycling occurs. This is associated with an increase in CaMKII- but not PKA-dependent RyR2 phosphorylation. CaMKII inhibition may thus reflect a promising therapeutic target for the treatment of arrhythmias and contractile dysfunction.
BACKGROUND: Sarcoplasmic reticulum (SR) Ca(2+) leak through ryanodine receptor type 2 (RyR2) dysfunction is of major pathophysiological relevance in humanheart failure (HF); however, mechanisms underlying progressive RyR2 dysregulation from cardiac hypertrophy to HF are still controversial. METHODS AND RESULTS: We investigated healthy control myocardium (n=5) and myocardium from patients with compensated hypertrophy (n=25) and HF (n=32). In hypertrophy, Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) and protein kinase A (PKA) both phosphorylated RyR2 at levels that were not different from healthy myocardium. Accordingly, inhibitors of these kinases reduced the SR Ca(2+) leak. In HF, however, the SR Ca(2+) leak was nearly doubled compared with hypertrophy, which led to reduced systolic Ca(2+) transients, a depletion of SR Ca(2+) storage and elevated diastolic Ca(2+) levels. This was accompanied by a significantly increased CaMKII-dependent phosphorylation of RyR2. In contrast, PKA-dependent RyR2 phosphorylation was not increased in HF and was independent of previous β-blocker treatment. In HF, CaMKII inhibition but not inhibition of PKA yielded a reduction of the SR Ca(2+) leak. Moreover, PKA inhibition further reduced SR Ca(2+) load and systolic Ca(2+) transients. CONCLUSIONS: In humanhypertrophy, both CaMKII and PKA functionally regulate RyR2 and may induce SR Ca(2+) leak. In the transition from hypertrophy to HF, the diastolic Ca(2+) leak increases and disturbed Ca(2+) cycling occurs. This is associated with an increase in CaMKII- but not PKA-dependent RyR2 phosphorylation. CaMKII inhibition may thus reflect a promising therapeutic target for the treatment of arrhythmias and contractile dysfunction.
Entities:
Keywords:
calcium–calmodulin-dependent protein kinase type 2; heart failure; hypertrophy; protein kinases; sarcoplasmic reticulum
Authors: Kafa Walweel; Nieves Gomez-Hurtado; Robyn T Rebbeck; Ye Wint Oo; Nicole A Beard; Peter Molenaar; Cris Dos Remedios; Dirk F van Helden; Razvan L Cornea; Björn C Knollmann; Derek R Laver Journal: J Mol Cell Cardiol Date: 2019-03-27 Impact factor: 5.000
Authors: Lorenz H Lehmann; Zegeye H Jebessa; Michael M Kreusser; Axel Horsch; Tao He; Mariya Kronlage; Matthias Dewenter; Viviana Sramek; Ulrike Oehl; Jutta Krebs-Haupenthal; Albert H von der Lieth; Andrea Schmidt; Qiang Sun; Julia Ritterhoff; Daniel Finke; Mirko Völkers; Andreas Jungmann; Sven W Sauer; Christian Thiel; Alexander Nickel; Michael Kohlhaas; Michaela Schäfer; Carsten Sticht; Christoph Maack; Norbert Gretz; Michael Wagner; Ali El-Armouche; Lars S Maier; Juan E Camacho Londoño; Benjamin Meder; Marc Freichel; Hermann-Josef Gröne; Patrick Most; Oliver J Müller; Stephan Herzig; Eileen E M Furlong; Hugo A Katus; Johannes Backs Journal: Nat Med Date: 2017-12-11 Impact factor: 53.440
Authors: Itamar Couto Guedes Jesus; Thássio Ricardo Ribeiro Mesquita; André Luís Lima Monteiro; Amanda Borges Parreira; Anderson Kenedy Santos; Elizeu Lucas Xavier Coelho; Mário Morais Silva; Lucas A C Souza; Maria José Campagnole-Santos; Robson Souza Santos; Silvia Guatimosim Journal: Am J Physiol Cell Physiol Date: 2020-01-08 Impact factor: 4.249
Authors: Jiali Nie; Quanlu Duan; Mengying He; Xianqing Li; Bei Wang; Chi Zhou; Lujin Wu; Zheng Wen; Chen Chen; Dao Wu Wang; Katherina M Alsina; Xander H T Wehrens; Dao Wen Wang; Li Ni Journal: J Cell Physiol Date: 2018-11-29 Impact factor: 6.384